Trial Profile

A Phase 2b, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2015 After the US FDA indicated that La Jolla Pharmaceutical Company is required to conduct additional chemical characterisation of GCS-100 prior to further clinical development, the company announced its decision to discontinue its galectin-3 inhibitor program. It will continue to treat and follow patients already enrolled in this phase IIb study but will stop enrolling new patients, according to a media release.
07 May 2015 Status changed from recruiting to active, no longer recruiting, according to a La Jolla Pharmaceutical Company media release.
18 Mar 2015 Status changed from not yet recruiting to recruiting, as reported by La Jolla Pharmaceutical Company media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com